Company Performance - iRhythm Technologies reported a quarterly loss of $0.32 per share, better than the Zacks Consensus Estimate of a loss of $0.53, and an improvement from a loss of $0.61 per share a year ago, resulting in an earnings surprise of +39.62% [1] - The company posted revenues of $186.69 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 7.47%, and up from $148.05 million in the same quarter last year [2] - Over the last four quarters, iRhythm Technologies has surpassed consensus EPS estimates two times and topped consensus revenue estimates four times [2] Stock Performance - iRhythm Technologies shares have increased approximately 55.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.2% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.38 on revenues of $173 million, and for the current fiscal year, it is -$1.92 on revenues of $695.48 million [7] Industry Outlook - The Medical Info Systems industry, to which iRhythm Technologies belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Company Performance - Evolent Health reported quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.09 per share, and down from $0.34 per share a year ago, representing an earnings surprise of -33.33% [1] - The company posted revenues of $483.65 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 4.76%, but down from $639.65 million year-over-year [2] - Over the last four quarters, Evolent Health has surpassed consensus EPS estimates just once and topped consensus revenue estimates two times [2] Stock Outlook - Evolent Health shares have declined approximately 7.1% since the beginning of the year, compared to a decline of -4.3% for the S&P 500 [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to those expectations [4] - The current consensus EPS estimate for the coming quarter is $0.10 on revenues of $492.27 million, and for the current fiscal year, it is $0.42 on revenues of $2.07 billion [7] Industry Context - The Internet - Software industry, to which Evolent Health belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Evolent Health's stock performance [5] - Another company in the same industry, Guidewire Software, is expected to report quarterly earnings of $0.46 per share, reflecting a year-over-year change of +76.9% [9]